Recently, Morel et al. reported that EZH2 depletion/inhibition upregulated IFN pathways and potentiated response to PD-1 therapy in prostate cancer [68], which may be similar for MRT and ovarian cancers. This evidence concerns the gene EZH2 and Familial prostate cancer.